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Abstract
Purpose Myocardial infarction (MI) results in an increased
susceptibility to ventricular arrhythmias, due in part to de-
creased inward-rectifier K+ current (IK1), which is mediated
primarily by the Kir2.1 protein. The use of renin-angiotensin-
aldosterone system antagonists is associated with a reduced
incidence of ventricular arrhythmias. Casein kinase 2 (CK2)
binds and phosphorylates SP1, a transcription factor of
KCNJ2 that encodes Kir2.1. Whether valsartan represses
CK2 activation to ameliorate IK1 remodeling following MI
remains unclear.
Methods Wistar rats suffering from MI received either
valsartan or saline for 7 days. The protein levels of CK2 and
Kir2.1 were each detected via a Western blot analysis. The
mRNA levels of CK2 and Kir2.1 were each examined via
quantitative real-time PCR.
Results CK2 expression was higher at the infarct border; and
was accompanied by a depressed IK1/Kir2.1 protein level.
Additionally, CK2 overexpression suppressed KCNJ2/Kir2.1
expression. By contrast, CK2 inhibition enhanced KCNJ2/
Kir2.1 expression, establishing that CK2 regulates KCNJ2
expression. Among the rats suffering from MI, valsartan re-
duced CK2 expression and increased Kir2.1 expression com-
pared with the rats that received saline treatment. In vitro,
hypoxia increased CK2 expression and valsartan inhibited
CK2 expression. The over-expression of CK2 in cells treated
with valsartan abrogated its beneficial effect on KCNJ2/
Kir2.1.
Conclusions AT1 receptor antagonist valsartan reduces CK2
activation, increases Kir2.1 expression and thereby amelio-
rates IK1 remodeling after MI in the rat model.
Keywords Myocardial infarction . CK2 . Kir2.1 .
Valsartan . Rat
Introduction
Ventricular arrhythmias following myocardial infarction (MI)
remain a major cause of mortality [1]. Numerous studies have
confirmed that decreased inward-rectifier K+ current (IK1),
along with the decreased expression of KCNJ2 mRNA and
its encoded Kir2.1 protein, is a prominent feature of ventricu-
lar electrical remodeling following MI [2–4]. IK1 is the pri-
mary K+ current that maintains resting membrane potential,
controls cardiac excitability and modulates both late-phase
repolarization and action potential duration (APD) in cardiac
cells. Furthermore, IK1 plays an important role in cardiac
excitability and arrhythmogenesis and is a promising target
for new antiarrhythmic approaches [5].
The mechanism underlying IK1 dysregulation following
MI primarily involves intracellular signaling pathways. How-
ever, the gene regulation of these pathways is poorly under-
stood. Recent studies have discovered that CK2 is associated
with several diseases, such as cardiac hypertrophy [6], and is
also involved in ion channel regulation [7, 8]. Additionally,
several studies have demonstrated that CK2 binds to and in-
duces the phosphorylation of transcription factor SP1 serine,
resulting in the suppression of gene expression [9, 10]. SP1 is
also an important transcription factor for KCNJ2 [11].
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Therefore, we hypothesized that CK2 regulates KCNJ2/
Kir2.1/IK1 expression via CK2.
The use of renin-angiotensin-aldosterone system (RAAS)
antagonists is associated with a reduced incidence of malig-
nant arrhythmias [12]. Therefore, we used a rat model ofMI to
determine whether the angiotensin type 1 receptor antagonist,




The animals were handled and all procedures were performed
in accordance with the regulations of the Guide for the Care
and Use of Laboratory Animals, published by the United
States National Institutes of Health (NIH publication no. 85–
23, revised 1996) and approved by the Animal Care and Use
Committee of Shandong University.
Cell Culture
The H9c2 (Wistar rat embryonic ventricle) cell line used in
this study was purchased from ATCC (Zhongyuan Ltd., Bei-
jing, China) and cultured in DMEM.
Cardiomyocyte Isolation and Primary Cell Culture
The enzymatic dispersion techniques used to isolate single
ventricular myocytes from neonatal Wistar rats have been de-
scribed previously in detail [13]. Briefly, 1- to 3-day-old rats
were decapitated, and their hearts were removed in a sterile
manner. The apex of each heart was dissected, minced, and
trypsinized at 37 °C for 10 min. Dissociated cells were plated
in 6-well plates in DMEM (Invitrogen) containing 10 % FBS,
and the nonadherent cardiomyocytes were removed. The cells
(1–2 *105/well) were seeded onto a 6-well plate for further
experiments. This procedure yielded cultures with 80±10 %
myocytes, as assessed via the microscopic observation of the
cells.
Drug Treatment
The CK2 inhibitor, 4,5,6,7-tetrabromo-2-azabenzimidazole
(TBB), was purchased from the Sigma-Aldrich Company
(Sigma, St. Louis, MO, USA). TBB was dissolved in 100 %
dimethylsulphoxide (DMSO; Sigma) to make a stock solution
of 10mM, which was then diluted in culture medium to obtain
the desired concentration of 100 μM [14, 15]. Untreated cells
were incubated in culture medium without any additives. The
cells were treated either with or without TBB for 48 h.
CoCl2 (300 μM) (Sigma, St. Louis, MO, USA) and
valsartan (20 μM) (Novartis Pharma AG, Basle, Switzerland)
were prepared in double distilled water, diluted with culture
media and cultured for 48 h. The doses of both CoCl2 and
valsartan were similar to those used in previous studies [16,
17].
Transfection Procedures
To achieve the transient overexpression of CK2, neonatal rat
ventricular myocytes and H9c2 cells were transfected with
pcDNA6-CK2α at a dose of 2.0 μg/mL, using N-[1(2,
3dioleoyloxyl)propyl]-N,N,N-trimethylammoniummethylsulfate
(DOTAP) for a period of 24 h, as was performed in previous
studies [18, 19]. The cells were transfected for 48 h.
MI Model
Male Wistar rats (8 weeks-of-age, 250–300 g); provided by
the Animal Facilities of Shandong University, China; were
anesthetized with an intraperitoneal injection of 3 % sodium
pentobarbital (40 mg/kg; Sigma-Aldrich, St. Louis, Mo.,
USA). The animals underwent a thoracotomy and
pericardiotomy, and the left anterior descending coronary ar-
tery was ligated to induce an MI as previously described [20].
The sham rats (n=10) underwent a thoracotomy and
pericardiotomy without coronary artery ligation. The MI rats
received either oral valsartan (10 mg/kg/day once a day, n=
10) or an equivalent volume of saline (n=10) for 7 days, be-
ginning on the day after the operation. The dose of valsartan
was similar to that used in previous studies [21].
Heart Tissue Preparation
The heart was rapidly excised, sliced along the edges of the
infarction, and dissected along the infarct border. The middle
portion included the entirety of the infarcted myocardium and
was immersed in 10 % formalin for 24 h, embedded in paraf-
fin, cut into 10-μm sections and stained with Masson’s
trichrome (Fig. 1). We sampled the corresponding heart posi-
tions in the sham rats.
qPCR Analysis
We conducted qPCR experiment as previously described [22,
23]. Briefly, total RNAwas extracted from the rat hearts, the
H9c2 cells and the primary ventricular myocytes using Trizol
(Invitrogen, Carlsbad, Calif., USA), before being reverse-
transcribed using a PrimeScript RT reagent kit (TaKaRa Bio-
technology, Dalian, China). Real-time PCR was performed
using a SYBR Premix Ex Taq (TaKaRa) in a Master-cycler
EP Realplex detection system (Roche, USA), according to the
manufacturer’s instructions. Each measurement was
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performed in triplicate. The data analysis was performed using
the 2–△△CT method [24]. The primer sequences were as fol-
lows: Kir2.1, forward: 5′- TGCCCGATTGCTGTTTTC-3′,
and reverse: 5′- GGCTGTCTTCGTCTATTT- 3′; CK2, for-
ward: 5′- GTGGTGGAATGGGGAAATCAAGA -3′, and re-
verse: 5′- GTATCGGGAAGCAACTCGGACAT- 3′; β-actin,
forward: 5′- ACCACAGTCCATGCCATCAC-3′, and re-
verse: 5′-TCCACCACCCTGTTGCTGTA-3′.
Western Blot Analysis
Protein samples were extracted from the infarct border zones
of the rat hearts, from cultured neonatal rat ventricular
myocytes and from H9c2 cells utilizing procedures described
in detail elsewhere [17]. Nuclear and cytoplasmic proteins
were isolated using a Nuclear and Cytoplasmic Protein Ex-
traction Kit (Beyotime Institute of Biotechnology, Jiangsu,
China). Protein content was determined using the BCA Pro-
tein Assay Kit (Beyotime).
Equal amounts of protein samples were fractionated using
SDS-PAGE (6–12 % polyacrylamide gels) and transferred
onto polyvinylidene difluoride membranes (Bio-Rad, Rich-
mond, Va., USA), which were blocked with 10 % bovine
serum albumin (Sigma-Aldrich) and incubated overnight at
4 °C with either rabbit anti-Kir2.1 (1:1500; Epitomics, Bur-
lingame, Calif., USA) or rabbit anti-CK2alpha (1:1000,
Abcam, Cambridge, MA, USA), followed by incubation with
horseradish peroxidase-conjugated secondary goat anti-rabbit
antibodies (1:10,000; Zhong Shan Golden Bridge Biotechnol-
ogy). The relative expression levels of the target proteins were
normalized using an anti-β-actin (1:5000; Proteintech, Chica-
go, USA) antibody. Imaging was performed using the
FluroChem E Imager (ProteinSimple, Santa Clara, Calif.,
USA), with an enhanced chemiluminescence system
(Millipore), and signal intensities were quantified using Image
J software. The final results are expressed as fold changes by
normalizing the data to the control values.
Whole-Cell Patch-Clamp Recording
Patch-clamp techniques were applied to cultured neonatal rat
ventricular myocytes transfected with miRNA or AMOs or
negative control constructs. The pipettes used for the patch
electrodes had tip resistances of 2 to 3 MΩ when filled with
pipette solution. The cells were placed in a 1 ml chamber
mounted on an inverted microscope (DMI3000 B; LEICA)
and perfused with Tyrode’s solution. Whole-cell recording
was performed using a patch EPC10 single amplifier (HEKA
Instruments). The signals were filtered at 1 kHz, and the data
were acquired via A/D conversion (LIH1600; HEKA Instru-
ments). The ion currents were recorded in the whole-cell volt-
age-clamp mode. For the recordings of IK1, the pipette solu-
tion contained 130 mM KCl, 0.4 mM Na-GTP, 3 mM Mg-
ATP, 0.5 mMEGTA, and 25mMHEPES (pH 7.2 with KOH);
the external Tyrode’s solution contained 135mMNaCl, 4 mM
KCl, 1.8 mM CaCl2, 1 mM MgCl2, 2 mM HEPES, and
11 mM dextrose (pH 7.4 with NaOH). CoCl2 (0.1 μM) and
tetrodotoxin (10 μM) were both included to inhibit IcaL and
INa, respectively. The experiments were conducted at room
temperature. Series resistance and capacitance were compen-
sated, and leak currents were subtracted. Cells with consider-
able leak currents were removed from the analysis. The data
were collected using an IBM-compatible computer and ana-
lyzed using PatchMaster.
IK1 was recorded with 200-ms square-wave pulses at volt-
ages ranging from −120 mV to 0 mV with a holding potential
of −80 mV [25, 26]. Individual currents were normalized to
the membrane capacity to control for differences in cell size
and are expressed as current densities (pA/pF).
Electrophoretic Mobility Shift Assay (EMSA)
An EMSAwas carried out as described previously [10]. The
sequences of the oligonucleotides used for the EMSAwere as
follows: −31/+8, 5′-GTCACTTAAACAGCTGTGCAGTGG
Fig. 1 Representative histologic
image of the heart stained with
Masson’s Trichrome. Myocytes
are red and fibrotic tissues are
blue. Left: after the sham surgury.
Right: after the MI surgury
















Nuclear protein extracts were prepared using a commer-
cially available kit (Viagene Biotechnology, Jiangsu, China).
The EMSA involved the use of a nonradioactive EMSA kit
(Viagene). Briefly, equal amounts of nuclear protein were in-
cubated with poly dI:dC for 20 min at room temperature in
binding reaction buffer. The specificity of the binding was
examined via competition with an unlabeled oligonucleotide.
The DNA-protein complexes were resolved on a 6.5 % poly-
acrylamide gel preelectrophoresed in 0.25 × Tris borate/
EDTA at 120 V for 1 h. The gel was subsequently transferred
onto a positively charged nylon membrane. The transferred
DNA was cross-linked to the membrane and detected using
horse- radish peroxidase-conjugated streptavidin.
Data Analysis
The statistical analysis was performed using SPSS 10.5 soft-
ware. The data are presented as the means±standard devia-
tions (SDs). The differences among multiple groups were
assessed using a one-way analysis of variance (ANOVA),
and a Tukey’s post-hoc test was used to evaluate the signifi-
cance of the differences between 2 groups. A two-tailed
P<0.05 was indicative of a statistically significant difference.
The number of rats or cells for each group is 10.
Results
The Dysregulation of CK2 and KCNJ2/Kir2.1 in the MI
Rats
In an effort to determine the role of CK2 in acute myocardial
infarction (AMI), we found that CK2 was significantly upreg-
ulated. Consistent with the findings of previous studies
[27–29], we found that Kir2.1 protein expression was down-
regulated in MI rats (Fig. 2). Besides, the KCNJ2 mRNA
expression was also downregulated during the healing phase
after AMI, suggesting that the regulation of Kir2.1 protein at
7 days after MI is not only on translation but also on mRNA
level. These results are consistent with the hypothesis that
CK2 contributes to KCNJ2 dysregulation in the setting of
MI, a possibility that we elected to test directly.
The Validation of KCNJ2 as a Target for CK2
Adding CK2 inhibitor TBB after the transfection of CK2 into
either H9c2 cells or rat primary ventricular cells produced a
marked inhibition of CK2 activity (Fig. 3a). Kir2.1 protein
expression is significantly downregulated compared with the
sham-treated control cells after the transfection of CK2 . And
this repression was efficiently rescued by suppressing CK2
activity with TBB (100 μM) (Fig. 3a).KCNJ2mRNA expres-
sion was also decreased by CK2 (Fig. 3a). We subsequently
verified the effects of CK2 at the functional level. IK1 was
determined in neonatal rat ventricular cells using whole-cell
patch-clamp techniques. The cells transfected with CK2 had a
lower IK1 density than the control cells, and the difference
was eliminated by adding TBB or valsartan (Fig. 3b). The
regulation of the KCNJ2 gene by CK2 was confirmed via an
EMSA, which indicated that CK2 phosphorylates Sp1 to sup-
press KCNJ2 expression, and the CK2 inhibitor, TBB, elimi-
nates this effect (Fig. 3c).
Valsartan Inhibits CK2 to Protect KCNJ2/Kir2.1
Following MI
To determine whether valsartan treatment inhibited electrical
remodeling following MI, we tested the expression of CK2
and KCNJ2/Kir2.1. In vivo, the upregulation of CK2 and the
downregulation of KCNJ2/Kir2.1 followingMIwere reversed
by valsartan, indicating that valsartan inhibited CK2 to reduce
Kir2.1 remodeling following MI (Fig. 4a). In vitro, hypoxia
increased CK2 expression, and valsartan reduces the increased
CK2 expression induced by CoCl2 (Fig. 4b). The over-
expression of CK2 in cells treated with valsartan abrogated
its beneficial effect on KCNJ2/Kir2.1 (Fig. 4c). Additionally,
as the EMSA results indicate, valsartan eliminated the phos-
phorylation effect of CK2 on Sp1, resulting in a higherKCNJ2
expression level than in the CK2 group (Fig. 4d).
Valsartan has Insignificant Effects on Kir2.1 Expression
Without Active CK2
To identify whether TBB and valsartan have an effect on
Kir2.1 expression through the endogenous CK2, we intro-
duced TBB and valsartan onH9c2 rat ventricular cells without
CK2 intervention. Both TBB and valsartan have insignificant
inhibitory effects on the endogenous CK2 as well as Kir2.1
expression (Fig. 5). This phenomenon further indicated that
valsartan improves KCNJ2/Kir2.1 mostly depending on acti-
vated CK2 after MI. While under physiological conditions
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endogenous CK2 has low activity, leading to weak regulation
on Kir2.1 expression.
Discussion
Taken together, our results indicate that CK2 is a potentially
important regulator of KCNJ2 gene expression and an
important determinant of cardiac electronic instability follow-
ing MI, via IK1. Additionally, our findings indicate that
CK2 is a potential mediator of the electrophysiological
effects of valsartan and provide a basis for the improve-
ment of IK1 remolding facilitated by valsartan. There-
fore, our study has revealed what we believe to be a
novel molecular control mechanism of ion channel re-
modeling following MI.
Fig. 2 The upregulation of CK2 and the downregulation of KCNJ2/
Kir2.1 in MI rats. A qPCR analysis and a Western blot analysis
demonstrating the significant upregulation of CK2 and the
downregulation of Kir2.1 in ventricular myocytes at a ventricular
infarct border in a rat MI model. Similar results showing in
noninfarcted LVFW of MI rats. *P<0.05 vs. control; n=10/group.
Values are expressed as the means±SDs
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Fig. 3 The regulation of Kir2.1
expression by CK2. a A qPCR
analysis and a Western blot
analysis demonstrating the CK2
level after transfection (n=10)
and inhibition by TBB (n=10)
and the effects of CK2 (n=10)
and its inhibition (TBB; n=10) on
Kir2.1 protein expression in H9c2
rat ventricular cells. *P<0.05 vs.
control; †P<0.05 vs. CK2 alone.
b IK1 density in cultured neonatal
rat ventricular cardiomyocytes.
IK1 was elicited by 200-ms
pulses at the indicated voltages.
*P<0.05 vs. control; n=10/
group. c Autoradiograms and the
EMSA quantification of Sp1
DNA-binding activity in H9c2 rat
ventricular cells. The data are the
fold values of DNA-binding
activity in the CK2 + TBB group
compared with the CK2 group.
*P<0.05 vs. control; †P<0.05 vs.
CK2 alone; n=10/group. Values
are means±SDs
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Fig. 4 Valsartan inhibited CK2 and protected KCNJ2/Kir2.1. a qPCR
and immunoblots depicting the effect of valsartan on both CK2 and
Kir2.1 in infarcted border and noninfarcted LVFW in MI rats. Both the
upregulation of CK2 and the downregulation of Kir2.1 following MI
were reversed by valsartan. *P<0.05 vs. control; †P<0.05 vs. MI; n=
10/group. b qPCR and immunoblots depicting the effect on CK2 in H9c2
cells. The upregulation of CK2 by hypoxia induced by CoCl2 was
depressed by valsartan. *P<0.05 vs. control; †P<0.05 vs. CoCl2; n=10/
group. c qPCR and immunoblots depicting the effect on Kir2.1. The
downregulation of Kir2.1 by hypoxia was improved by valsartan.
Additionally, the over-expression of CK2 in the cells treated with
valsartan abrogated this effect. *P<0.05 vs. control; †P<0.05 vs. CoCl2;
#P<0.05 vs. CoCl2 + valsartan; n=10/group. d Autoradiograms and the
EMSA quantification of Sp1 DNA-binding activity in rat hearts. The data
are the fold values of DNA-binding activity in the MI+valsartan group
compared with the MI group. *P<0.05 vs. control; †P<0.05 vs. CK2; n=
10/group. Values are means±SDs
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Cardiac IK1 current is a strong inward rectifying K+ selec-
tive current and plays an important role in shaping normal
cellular action potentials [30]. Cardiac IK1 stabilizes the cel-
lular resting membrane potential and is responsible for shap-
ing both the initial depolarization and the final repolarization
of the action potential [31, 32]. Studies indicate that IK1 plays
a role in ventricular arrhythmias, as illustrated by the recently
described Andersen’s syndrome and studies utilizing guinea
pig heart models of ventricular fibrillation [33]. Most of the
research regarding the potential role of CK2 in cardiac patho-
physiology has been focused on cardiac hypertrophy but has
rarely focused on ion channel remodeling. Our findings indi-
cate that CK2 regulates this important K+ channel under spe-
cific disease conditions. Further studies regarding the CK2-
mediated dysregulation of IK1 in other pathological contexts
may be of interest.
AT1 receptor blockers prevent ventricular dilation, dys-
function, and cardiac hypertrophy in non-infarcted myocardial
tissue following MI. Some of the effects observed in patients
in the setting of baseline use of RAAS inhibition are related to
decreased electrical irritability, which is due primarily to the
well-established effects exerted by ARBs on remodeling and
the preservation of LV systolic function [34, 35]. Our study
showed that valsartan ameliorates KCNJ2/Kir2.1 remodeling
during the healing phase after MI when significant structural
remodeling also accurs.
CK2 (formerly casein kinase II or CKII) is a ubiquitous
protein Ser/Thr kinase with a heterotetrameric structure
consisting of two catalytic subunits (42 kDa α and 38 kDa
α′) and two regulatory subunits (28 kDa β). CK2 phosphory-
lates a large number of substrates with various functions relat-
ed to cell growth and proliferation. However, its electrophys-
iological effects have seldom been explored. In this study, we
firstly investigated CK2 and Kir2.1 mRNA and protein levels
in infarcted border and noninfarcted LVFW (left ventricular
free wall) seperately to eliminate the different effects of cell
necrosis and myocardial remodeling degrees on the levels of
mRNA and protein expression. We found that CK2 was acti-
vated in vivo following MI and in vitro after the cells were
induced to be hypoxia, which resulted in decreased Sp1 DNA
binding activity. As a result, the expression of KCNJ2, the
flow gene of SP1, was downregulated, as was the expression
of Kir2.1 and IK1 current. This effect was repressed by the
highly selective cell permeable CK2 inhibitor, TBB, and
valsartan. TBB blocks in vitro CK2 activation under hypoxia
condition. But as shown in Fig. 5, TBB has little effect on
endogenous CK2 in non-hypoxia cells. Valsartan presents a
similar effect on CK2 regulation. Without active CK2, both
Fig. 5 TBB and valsartan have
insignificant inhibition effect on
the endogenous CK2 as well as
Kir2.1 expression. qPCR and
immunoblots depicting the effect
of TBB and valsartan on CK2 and
Kir2.1 in H9c2 cells. Each group
had no statistical significance. n=
10/group. Values are means±SDs
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TBB and valsartan have a weak effect on Kir2.1 protein ex-
pression. This indicates that CK2 is the main factor mediating
the regulation of valsartan on Kir2.1 during the healing phase
after AMI.
The mechanism of valsartan inhibiting the actions of CK2
might have two explanations. On the one hand, CK2 might be
one downstream protein of AT1 receptor. On the other hand,
valsartan has off target effects. Interestingly, CK2 may be
activated by AT1 and AT2-activated SHP-1 inactivates CK2
[36]. Indeed, cytoplasmic CK2-alpha’-dependent kinase ac-
tivity is induced by angiotensin II [37]. Therefore, CK2 seems
to be activated by AT1 and inactivated by AT2. After MI, both
AT1 and AT2 receptor levels increase. But the degree of up-
regulated AT1 is higher [38]. Besides, angiotensin II has
higher affinity to AT1 than to AT2 [39]. This may explain
why CK2 increased after MI in our study and valsartan is
efficient in reducing its level.
In conclusion, we have discovered that CK2 regulates the
KCNJ2 gene and its encoded channel, IK1. Moreover,
valsartan regulates CK2 to improve cardiac ion channel re-
modeling following MI. But this regulation path still remains
to be shown using genetic models. Besides, the improvement
of valsartan to IK1 remodeling may contribute to reduced
susceptibility to ventricular arrhythmias during the healing
phase of MI and this hypothesis needs to be further demon-
strated in vivo. These are two major limitations of our exper-
iment. These findings have provided us with new insights into
the molecular mechanisms underlying the cardiac electrical
instability that occurs following MI and may represent a treat-
ment strategy for other conditions in which IK1 is
dysregulated.
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